In 85 patients undergoing laparoscopic surgery for benign adnexal tumors, higher BMI was linked to increased abdominal wall thickness but did not significantly prolong primary trocar insertion using the open technique. Complication rates were comparable, highlighting the role of surgical experience.
Source : https://pubmed.ncbi.nlm.nih.gov/41769479/
Internal hernia is a recognized late complication of Roux-en-Y gastric bypass (RYGB), often occurring through mesenteric defects at the jejunojejunostomy (JJ) or Petersen's space. While most hernias result from anatomical...
Case report describes rare enteroenteric fistula–induced internal hernia causing small-bowel obstruction years after Roux-en-Y gastric bypass, successfully treated with robotic laparoscopic fistula excision and rapid postoperative recovery.
Did you know? Obesity-related systemic inflammation can reshape the tumor microenvironment and influence the efficacy and toxicity of immune checkpoint inhibitors in lung cancer. Adipokines, body composition metrics, and inflammatory biomarkers may help explain the “obesity paradox” and predict immune-related adverse events, including endocrine toxicities.
Could integrating obesity-related inflammatory biomarkers improve risk stratification and personalization of immunotherapy in lung cancer?
Could integrating obesity-related inflammatory biomarkers improve risk stratification and personalization of immunotherapy in lung cancer?
Source : https://pubmed.ncbi.nlm.nih.gov/41754837/
Introduction : Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has demonstrated unprecedented efficacy in the treatment of type 2 diabetes mellitus (T2DM) and obesity. However, its rapid clinical widespread use...
This review finds semaglutide maintains a favorable benefit-risk profile, with no confirmed increased cancer risk in humans and emerging cardioprotective effects, including potential mitigation of anticancer therapy–related cardiotoxicity, warranting continued monitoring.
As of 2025, the obesity treatment landscape continues to evolve. Injectable GLP-1 receptor agonists have set new clinical benchmarks, achieving 15–20% average weight reduction and improving cardiometabolic outcomes in adults with obesity. Yet real-world use often lags, hampered by injection hesitancy, supply constraints, and insurance variability.
Emerging research suggests the next frontier may lie with oral GLP-1–based therapies. In phase 3 studies, these agents have delivered weight reductions of 14–15%, closely mirroring injectables. Meanwhile, early-phase data on dual and triple agonists targeting GLP-1, glucagon, and amylin pathways show promising results, with up to 24% reductions reported in select populations. Gastrointestinal effects remain the most common treatment-related events and are typically mild and transient.
As these therapies near clinical integration, clinicians must consider how oral options will complement current care models—aligning with behavioral interventions, supporting adherence, and broadening access. Framing obesity as a chronic, manageable disease remains key, with new therapies positioned as tools for long-term metabolic health.
Pharmacologic therapy—oral or injectable—should enhance, not replace, nutritional, behavioral, and physical activity strategies. As HCPs, your role is pivotal in ensuring optimal treatment pairing and fostering durable outcomes.
Which of your patients might be best suited for oral anti-obesity therapy once available? What strategies have been most effective in supporting adherence and tracking response over time?
